Research programme: anti-emesis therapeutics - Myriad Pharmaceuticals

Drug Profile

Research programme: anti-emesis therapeutics - Myriad Pharmaceuticals

Alternative Names: MPC-4505

Latest Information Update: 13 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Myriad Genetics
  • Class
  • Mechanism of Action Neurokinin 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Nausea and vomiting

Most Recent Events

  • 13 Aug 2007 Discontinued - Preclinical for Nausea and vomiting in USA (unspecified route)
  • 15 Jan 2007 Preclinical development is ongoing
  • 21 Apr 2004 Preclinical trials in Emesis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top